-
Penalty or fake fall: Arvinas announced the second phase clinical data of the ER PROTAC drug ARV-471
Time of Update: 2023-01-05
On November 23, Arvinas, a star company of PROTAC, announced the preliminary results of the Phase II expansion trial (NCT04072952, code VERITAC) of its core pipeline ARV-471 for the treatment of sever
-
The latest clinical data of the star PROTAC project ARV-471 has obvious safety advantages
Time of Update: 2021-12-30
The study used a conventional 3+3 dose escalation study to evaluate the safety, pharmacokinetics, pharmacodynamics and preliminary effects of oral ARV-471 in pre/postmenopausal women with ER+/HER2-locally advanced or metastatic breast cancer Anti-tumor activity .
-
Pfizer acquires part of ARV-471 equity for 2.4 billion
Time of Update: 2021-08-05
[News event]: Pfizer announced today that it will acquire a partial interest in the estrogen receptor PROTAC drug ARV-471 developed by Arvinas, a pioneer in protein degradation, with a down payment of 650 million and a stock subscription of 350 million, plus 1.
-
The latest development of the world's first PROTAC drug ARV-110 and the pipeline layout are brief.
Time of Update: 2020-08-03
is optimistic about this technology, the company developed the world's first PROTAC drug ARV-110, intended to be used for the treatment of dedegeneration resistance prostate cancer, has entered the clinical Phase I phase of the study phase, clinical I initial data show that ARV-110 has good oral utilization and good safety and tolerance.
-
The world's first PROTAC drug ARV-110 latest developments and pipeline layout.
Time of Update: 2020-08-03
is optimistic about this technology, the company developed the world's first PROTAC drug ARV-110, intended to be used for the treatment of dedegeneration resistance prostate cancer, has entered the clinical Phase I phase of the study phase, clinical I initial data show that ARV-110 has good oral utilization and good safety and tolerance.
-
InD application for Arvinas candidate therapy ARV-471 obtains FDA approval
Time of Update: 2020-06-09
today, Pharmaceutical Sincon partner Arvinas (http:// announced that its application for inDD for its candidate therapy ARV-471 was approved by the FDA (http:// ARV-471 is an oral estrogen re